Showing 1581-1590 of 2656 results for "".
- OOTG Webcast: Weathering the Storm and Supporting Staffhttps://modernod.com/news/ootg-webcast-weathering-the-storm-and-supporting-staff/2477488/“Ophthalmology off the Grid” cohosts Gary Wörtz, MD, and Blake Williamson, MD, MPH, sat down—virtually—with Robert Weinstock, MD, and Elizabeth Yeu, MD, on March 27 to discuss how the COVID-19 crisis is
- FDA Accepts Oyster Point’s Filing of NDA for OC-01 Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/fda-accepts-oyster-points-filing-new-drug-application-for-oc-01-nasal-spray-for-the-treatment-of-signs-and-symptoms-of-dry-eye-disease/2478928/Oyster Point Pharma announced that the FDA has accepted its new drug application (NDA) for OC-01 (varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease. The Prescription Drug User Fee Act (PDUFA) target action date for OC-01 (varenicline) nasal spray is October 17, 2
- IACTA Pharmaceuticals and Pharmaleads to Develop the World’s First Epithelial Protective Drug Harnessing Endogenous Analgesia for the Topical Treatment of Acute and Chronic Ocular Painhttps://modernod.com/news/iacta-pharmaceuticals-and-pharmaleads-to-develop-the-worlds-first-epithelial-protective-drug-harnessing-endogenous-analgesia-for-the-topical-treatment-of-acute-and-chronic-ocular-pain/2478730/IACTA Pharmaceuticals and Pharmaleads announced they have entered into licensing agreements with IACTA acquiring global rights to Pharmaleads’ Dual Enkephalinase Inhibitors (DENKI), a novel class of non-opioid compounds for the treatment of acute and chronic ocular pain. “With
- Genentech’s Faricimab Meets Primary Endpoint and Shows Strong Durability Across Two Global Phase 3 Studies for DMEhttps://modernod.com/news/genentechs-faricimab-meets-primary-endpoint-and-shows-strong-durability-across-two-global-phase-3-studies-for-dme/2478687/Genentech announced positive topline results from two identically designed global phase 3 studies, YOSEMITE and RHINE, evaluating its investigational bispecific antibody, faricimab, in people living with diabetic macular edema (DME). Both studies met their primary endpoint and showed that
- FDA Accepts Santen’s NDA for Cyclosporine Topical Ophthalmic Emulsion for the Treatment of Severe Vernal Keratoconjunctivitis in Patients Ages 4-18https://modernod.com/news/fda-accepts-santens-nda-for-cyclosporine-topical-ophthalmic-emulsion-for-the-treatment-of-severe-vernal-keratoconjunctivitis-in-patients-ages-4-18/2478457/Santen announced that the FDA has accepted the new drug application (NDA) for cyclosporine topical ophthalmic emulsion 0.1% for the treatment of severe vernal keratoconjunctivitis (VKC) in patients ages 4-18. The FDA has set June 26, 2021 as the Prescription Drug Use
- Genentech’s Satralizumab Significantly Reduced Relapse Risk in Second Positive Phase 3 Study for Neuromyelitis Optica Spectrum Disorderhttps://modernod.com/news/genentechs-satralizumab-significantly-reduced-relapse-risk-in-second-positive-phase-3-study-for-neuromyelitis-optica-spectrum-disorder/2476875/Genentech presented full pivotal phase 3 study results for satralizumab as a monotherapy for neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating central nervous system disease. Results from the SAkuraStar study, presented at the 35th Congress of the European Committee for Treatme
- iSTAR Medical’s MINIject Shows Consistent Results at 18-Month Follow-Up in First-in-Human Trial (STAR-I)https://modernod.com/news/istar-medicals-miniject-shows-consistent-results-at-18-month-follow-up-in-first-in-human-trial-star-i/2476718/iSTAR Medical SA announced consistent 18-month results of the first-in-human, micro-invasive glaucoma surgery (MIGS) STAR-I trial for the MINIject device in a standalone setting. These results confirm the stability and sustained performance of MINIject beyond the first year, according to a compan
- A Single Course of Provention’s PRV-031 (Teplizumab) Delays Type 1 Diabetes Onset in High-Risk Individuals by at Least 2 Yearshttps://modernod.com/news/a-single-course-of-proventions-prv-031-teplizumab-delays-type-1-diabetes-onset-in-high-risk-individuals-by-at-least-2-years/2476644/Provention Bio announced that results from the National Institutes of Health (NIH)-sponsored “At-Risk” Study were published on-line in The New England Journal of Medicine and presented at the Scientific Sessions of the 79th Annual American Diabetes Association (ADA) meeting.
- Preclinical Studies Demonstrate Galimedix’s GAL-101 Shows Neuroprotective Effect from Toxic Amyloid-Beta in Dry AMD and Glaucoma Modelshttps://modernod.com/news/preclinical-studies-demonstrate-galimedixs-gal-101-shows-neuroprotective-effect-from-toxic-amyloid-beta-in-dry-amd-and-glaucoma-models/2476564/Galimedix Therapeutics presented data demonstrating its novel, first-in-class, investigational compound GAL-101 provides neuroprotection from misfolded amyloid beta molecules aggregating into toxic forms in vitro, neutralizing their ability to be toxic to neural tissues. Further, investiga
- iSTAR Medical’s MINIject Maintains Exceptional Results in First-in-Human Trial One Year Post-Surgery (STAR-I)https://modernod.com/news/istar-medicals-miniject-maintains-exceptional-results-in-first-in-human-trial-one-year-post-surgery-star-i/2476244/iSTAR Medical announced 1-year results of the first-in-human, microinvasive glaucoma surgery (MIGS) STAR-I trial, for the MINIject device in a standalone setting. Results demonstrate that MINIject is safe and highly effective in achieving significant IOP reduction, as well as easing medication bu